Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure.Zhou F et al. Leuk Lymphoma. 2014 Jan 28. [Epub ahead of print].Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?San Miguel JF. Haematologica. 2014 Jan;99(1):5-6. doi: 10.3324/haematol.2013.100982.Management of bone disease in multiple myeloma.Terpos E…
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. Palumbo A et al. J Clin Oncol. 2014 Jan 21. [Epub ahead of print]. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Merz M et…
This paper, written by an expert panel on behalf of the International Myeloma Working Group, outlines consensus recommendations for risk stratification for clinical and clinical trial use.
This NICE guidance outlines recommendations for the prevention, identification and management of neutropenic sepsis in people with cancer.
This paper, written by an expert panel of the International Myeloma Working Group, examines the impact of novel treatments on stem cell collection in myeloma patients. It summarises the available evidence and makes recommendations to address identified issues.
Following consultation on the scope of the guideline we have decided to retain Improving supportive and palliative care for adults with cancer. The title of the new guideline will be changed to End of life care for adults in the last year of life: service delivery. Where there is overlap between the two guidelines we…